Extract from our M&A Insights

Read more about our Nordic and DACH M&A Insights services including the M&A Portal and Private Equity Portfolio Tracker.
Lundbeck makes an offer to buy Prexton Therapeutics
March 19, 2018

Lundbeck makes an offer to buy Prexton Therapeutics for 100M EUR now and will pay up to 805M EUR down the line in case the drug Foliglurax reaches a set of milestones. One of the big winners is the Danish venture capital fund Sunstone Capital who owns approximately one-fifth of Prexton Therapeutics and bought their shares in 2015.

--
ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library. If you would like more insights on this deal or industry then send us an email at requests@nordicknowledgepartners.com